On Oct 28, major Wall Street analysts update their ratings for $Apellis Pharmaceuticals (APLS.US)$, with price targets ranging from $35 to $95.
J.P. Morgan analyst Anupam Rama maintains with a buy rating.
Wells Fargo analyst Derek Archila maintains with a hold rating, and maintains the target price at $43.
TD Cowen analyst Phil Nadeau maintains with a buy rating, and maintains the target price at $95.
Stifel analyst Annabel Samimy maintains with a buy rating, and maintains the target price at $84.
Piper Sandler analyst Biren Amin maintains with a hold rating, and maintains the target price at $40.
Furthermore, according to the comprehensive report, the opinions of $Apellis Pharmaceuticals (APLS.US)$'s main analysts recently are as follows:
The initiation of coverage on Apellis highlighted that complement inhibitors Syfovre and Izervay were approved for geographic atrophy with the goal of slowing atrophy growth in the retina, rather than on functional benefits such as vision improvement, which is the metric for anti-VEGFs in wAMD. Consultants, who are considered key opinion leaders, have a reserved stance towards recommending Syfovre or Izervay, with a projection that at their peak, only about 20%-25% of patients will be suitable candidates.
A recent survey of U.S. retinal specialists revealed ongoing expansion within the complement inhibitor class, with an uptick in prescriptions for both Syfovre and its competitor, Izervay. The findings further suggest that Syfovre not only retains its position as the market leader but also has a competitive edge when it comes to initiating treatment in new patients.
Here are the latest investment ratings and price targets for $Apellis Pharmaceuticals (APLS.US)$ from 6 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間10月28日，多家華爾街大行更新了$Apellis Pharmaceuticals (APLS.US)$的評級，目標價介於35美元至95美元。
摩根大通分析師Anupam Rama維持買入評級。
富國集團分析師Derek Archila維持持有評級，維持目標價43美元。
TD Cowen分析師Phil Nadeau維持買入評級，維持目標價95美元。
斯迪富分析師Annabel Samimy維持買入評級，維持目標價84美元。
派傑投資分析師Biren Amin維持持有評級，維持目標價40美元。
此外，綜合報道，$Apellis Pharmaceuticals (APLS.US)$近期主要分析師觀點如下：
Apellis的覆蓋範圍的啓動突顯出，輔助抑制劑Syfovre和Izervay已經獲得地理性萎縮的批准，旨在減緩視網膜萎縮的增長，而不是關注功能收益，比如視力改善，這是抗VEGF藥物在溼性年齡相關性黃斑變性治療中的衡量指標。被認爲是關鍵意見領袖的顧問對推薦Syfovre或Izervay持謹慎態度，預計在它們的高峰時期，只有大約20%-25%的患者將是合適的候選者。
美國視網膜專家最近的調查顯示出，輔助抑制劑類別內正在持續擴展，對於Syfovre和其競爭對手Izervay的處方增長明顯。研究結果進一步表明，Syfovre不僅保持着市場領導地位，而且在爲新患者啓動治療方面具有競爭優勢。
以下爲今日6位分析師對$Apellis Pharmaceuticals (APLS.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
